Traditional compound antihypertensive drugs Traditional compound antihypertensive drugs: Beijing Antihypertensive No. 0, compound antihypertensive tablets, regular medicine antihypertensive tablets, Zhenju antihypertensive tablets, etc., usually consist of a combination of central antihypertensive drugs, such as reserpine and colistin, vasodilators, dihydralazine and dihydralazine, ganglion blockers, guanethidine, diuretics, hydrochlorothiazide, small amounts of sedatives: clorazepam, mother-of-pearl, wild chrysanthemum and other Chinese herbal ingredients. The specific formula is as follows: Beijing Antihypertensive 0: each tablet contains hydrochlorothiazide 12.5mg, aminopterin 12.5mg, dihydralazine sulfate 12.5mg, and reserpine 0.1mg; compound antihypertensive tablets: each tablet contains reserpine 0.032mg, hydrochlorothiazide 3.lmg, vitamin B6l.0mg, calcium pantothenate 1.0mg, magnesium trisilicate 30mg, potassium chloride 30mg. Vitamin B61.0mg, dihydralazine 4.2mg, promethazine 2.lmg; Zhenju antihypertensive tablets: each tablet contains colistin 0.03mg, hydrochlorothiazide 5mg, rutin 20mg. These “platter” type compound domestic antihypertensive drugs were widely used in the treatment of hypertension in the 1970s and 1980s. At present, they are still widely used in the community and rural areas, and have made great contributions to the prevention and treatment of hypertension in China. However, with the development of evidence-based medicine, its disadvantages have gradually emerged. 1.Lisdexamfetamine may cause depression, gastrointestinal bleeding, bradycardia, brain cognitive dysfunction, may increase suicide, car accidents, etc., and has been listed as the first batch of drugs to be eliminated; 2.Colistin can affect the cognitive function of the brain; 3.Guanidine may cause “upright hypotension” in the elderly; 4.Hydrochlorothiazide may lead to hypokalemia, insulin resistance and uric acid. 4. Hydrochlorothiazide can lead to hypokalemia, insulin resistance and increased uric acid; 5. Dihydralazine has an increased risk of left ventricular hypertrophy; 6. Mother-of-pearl, wild chrysanthemum and other Chinese herbal ingredients can only improve symptoms, but have no antihypertensive effect. The components of traditional compound antihypertensive drugs (except diuretic hydrochlorothiazide) are not the first-line antihypertensive drugs (ACEI, ARB, calcium blocker, B-blocker and diuretic) recommended by medical association guidelines. In conclusion, traditional combination antihypertensive drugs lack evidence of cardiovascular and cerebrovascular benefit and are not recommended as long-term treatment for hypertensive patients, and should be used with caution, especially in elderly patients. However, if the patient’s affordability is limited, traditional combination antihypertensive drugs can still be used. Characteristics and advantages of new compounded antihypertensive drugs New compounded antihypertensive drugs: using small doses of fixed formulas for the treatment of hypertension, 1, various formulas from different angles, different mechanisms to lower blood pressure, to achieve additive or synergistic effect. In addition, the dose of each component is reduced after making the compound, the incidence of adverse reactions will also be reduced, and there may be antagonistic effects between components of adverse reactions, so that their incidence is reduced to a minimum or even offset each other. 2, the efficacy of compounded formulations is not equal to the single drug of each formula taken together. 3, Newer compounded formulations also have advantages from a health economics perspective. Although these drugs are more expensive, they can reduce the incidence of strokes, cardiovascular events, and disability in the long run, which is beneficial for individual patients, insurance companies, and society as a whole. Fourth, patients with hypertension need to take medication for life, and the ability of patients to take medication regularly is closely related to the effectiveness of treatment. Making a fixed dose of two or even more drugs into one tablet can improve patient compliance with long-term medication. The first-line antihypertensive drugs in our current hypertension control guidelines are: diuretics, calcium antagonists, angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor antagonists (ARB), and beta-blockers. The following drugs are recommended for combination: diuretics and alpha-blockers, diuretics and angiotensin-converting enzyme inhibitors (ACEI) or ARBs, dihydropyridine calcium antagonists and beta-blockers, calcium antagonists and ACEI or ARB, calcium antagonists and diuretics, alpha-blockers and beta-blockers. At present, the common combination formulations in China are: ARB/HCTZ: Hedgehog (Coxsartan 50mg/Hydrochlorothiazide 12.5mg), Megasol (Telmisartan/Hydrochlorothiazide), Amphenol, Irenpine (Irbesartan 150mg/Hydrochlorothiazide 12.5mg), Fodavin (Valsartan 80mg/Hydrochlorothiazide 12.5mg), ACEI/HCTZ: Pepcid (Pepcid) Priligy 2mg + indapamide 0.625mg), compound captopril tablets (captopril tablets 10mg/hydrochlorothiazide 6mg), norethindrone (bisoprolol 2.5mg + hydrochlorothiazide tablets 6.25mg). Compound Amiloride Hydrochloride Tablets (Amiloride 2.5mg/Hydrochlorothiazide 25mg;)